Ladiratuzumab vedotin targets LIV-1 using our proprietary antibody–drug conjugate (ADC) technology. LIV-1 is expressed in most metastatic breast cancers, as well as in melanoma, and prostate, ovarian, uterine, and cervical cancers.1
Proposed mechanism of action
Ladiratuzumab vedotin is an investigational agent. Its safety and efficacy have not yet been established.